Joint ACTRIMS-ECTRIMS Meeting
Related Meeting News
No B-cell depletion found in children of mothers with MS treated with ocrelizumab
In pregnant women with MS given ocrelizumab, treatment did not result in infant B-cell depletion after birth, and the drug was virtually undetectable in the bloodstream of mother and child, according to a poster from ECTRIMS 2024.
Diroximel fumarate linked to lower rate of severe infection in MS
Treatment with diroximel fumarate was linked to lower rates of severe infection compared with anti-CD20 monoclonal antibodies for adults of all ages with MS, according to a poster presented at ECTRIMS.
Early initiation of Kesimpta associated with lower rates of disability worsening in MS
Early initiation and continuation of Kesimpta in those with relapsing MS was associated with lower rates of disability worsening up to 6 years compared with those who switched medication, according to a presentation at ECTRIMS 2024.
Patient adherence higher with inebilizumab compared with other biologics for NMOSD
Among individuals who were prescribed approved biologics for neuromyelitis optica spectrum disorder, those on inebilizumab had significantly higher medication adherence, according to a study presented at ECTRIMS 2024.